 |
INFORMATION FOR SPONSOR-INVESTIGATORS SUBMITTING
INVESTIGATIONAL NEW DRUG APPLICATIONS (INDs)
An Investigational New Drug Application (IND) is a request for Food and Drug
Administration (FDA) authorization to administer an investigational drug to humans. Such
authorization must be secured prior to interstate shipment and administration of any new
drug that is not the subject of an approved new drug application.
IND regulations are contained in Title 21, Code of Federal Regulations, Part 312.
Copies of the regulations, further guidance regarding IND procedures, and additional forms
are available from the FDA Center for Drug Evaluation and Research, Drug Information
Branch (HFD-210), 5600 Fishers Lane, Rockville, Maryland 20857, telephone (301) 827-4573
or toll free at 1-888-INFOFDA. In addition, forms, regulations, guidances, and a wide
variety of additional information is available online at http://www.fda.gov/cder/. Forms may be accessed
directly at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html.
The following instructions address only the administrative aspects of preparing and
submitting an IND, and are intended primarily to provide assistance to individual
Sponsor-Investigator applicants, not pharmaceutical companies.
WHERE TO SEND THE APPLICATION:
The initial IND submission and each subsequent submission to the IND should be
accompanied by a Form FDA 1571 and must be submitted in triplicate (the original and two
photocopies are acceptable). Mailing addresses for initial IND submissions are:
| For a Drug: Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
5901-B Ammendale Rd.
Beltsville, Md. 20705-1266
|
For a Therapeutic Biological Product:
(http://www.fda.gov/cber/transfer/transfer.htm)
CDER Therapeutic Biological Products Document Room
Center for Drug Evaluation and Research
Food and Drug Administration
12229 Wilkins Avenue
Rockville, MD 20852 |
FILLING OUT THE FORM FDA 1571: (The numbers below correspond to the numbered
boxes on the Form FDA 1571.)
1. The sponsor is the person who takes responsibility for and initiates a clinical
investigation. The sponsor may be a pharmaceutical company, a private or academic
organization, or an individual. A Sponsor-Investigator is an individual who both
initiates and conducts a clinical investigation and under whose immediate direction the
investigational drug is being administered or dispensed. For administrative reasons,
only one individual should be designated as sponsor.
If a pharmaceutical company will be supplying the drug, but will not itself be
submitting the IND, the company is not the sponsor.
2. The date of submission is the date that the application is mailed to
FDA.
3. The address is the address to which written correspondence from FDA should be
directed. If this address is a post office box number, a street address must also be
provided.
4. The telephone number is the number where the sponsor is usually available during
normal working hours. A telephone number must be provided.
5. For name(s) of drug, list the generic name(s) and trade name, if
available. Also, state the dosage form(s).
6. If an emergency IND number was previously assigned by FDA, or the Form FDA 1571 is
being included with an amendment to the original IND, then that IND number should be
entered here; otherwise, the space should be left blank.
7. Self-explanatory.
8. This section is to be completed by pharmaceutical firms that are conducting clinical
studies in support of a marketing application. Sponsor-Investigators need not complete
this section.
9. It is necessary for the sponsor to submit certain information with an IND (such as
manufacturing and controls information, pharmacology and toxicology data, or data from
prior human studies) unless that information has previously been submitted to FDA, AND the
sponsor of the previously submitted information provides a letter authorizing FDA to refer
to the information. In this case, the letter of authorization including the file
identification (IND/DMF/NDA number) must be: 1) submitted to the authorizer's application
and, 2) included in the initial submission of the new sponsor's IND. The sole exception to
this requirement is when a marketed drug is used in the study, without modification to its
approved packaging, in which case the marketed drug product must be identified by trade
name, established name, dosage form, strength, and lot number.
10. Numbering of submissions is primarily intended for pharmaceutical firms.
Sponsor-Investigators do not have to complete this section.
11. For an original IND submission, only the "Initial
Investigational New Drug Application (IND)" box should be checked. For subsequent
submissions, check ALL the boxes that apply since the submission may contain more than one
type of information.
Requests to charge and Treatment Protocols must be submitted separately. Treatment INDs
and Treatment Protocols are special cases and are not intended for single patient use.
Before checking either of these boxes, the sponsor should be thoroughly familiar with the
cited regulations and contact the appropriate FDA reviewing division to discuss the
proposed treatment use.
12. For a Sponsor-Investigator IND, items 2, 3, and 4 may be briefly addressed in the
cover letter or in a summary.
Where the investigational drug is obtained from a supplier in a final dosage form,
items 5, 7, 8, and 9 may be referenced if authorization is given by the supplier (see
explanation in section 9 above). If the investigational drug is prepared or altered in any
way after shipment by the supplier, complete manufacturing (or compounding) and controls
information, including information on sterility and pyrogenicity testing for parenteral
drugs, must be submitted for that process in Item 7.
Item 6 requires that the protocol be submitted, along with information on the
investigators, facilities, and Institutional Review Board (copies of the completed Form
FDA 1572 with attachments would suffice for 6 b-d).
Item 7 also requires submission of either a claim of categorical exclusion from the
requirement to submit an environmental assessment or an environmental assessment (21 CFR
25.15[a]). When claiming a categorical exclusion, the sponsor should include the following
statements: "I claim categorical exclusion (under 21 CFR 25.31[e]) for the study(ies)
under this IND. To my knowledge, no extraordinary circumstances exist."
13. This section does not pertain to a Sponsor-Investigator.
14-15. For a pharmaceutical firm, the name of the person responsible for monitoring the
conduct of the clinical investigation, and reviewing and evaluating safety information,
should be entered. For Sponsor-Investigator INDs, the investigator has this
responsibility.
N.B. Certain important commitments that the IND sponsor makes by
signing the form FDA 1571 are listed below box 15.
16-17. For an IND sponsored by a pharmaceutical firm or research organization, the name
of the sponsor's authorizing representative would be entered and that individual must sign
the form For a Sponsor-Investigator IND, the Sponsor-Investigator should be named and must
sign the form.
18-19. Box 18 and 19 need not be completed if they duplicate boxes 3 and 4.
20. The date here is the date the form is signed by the sponsor.
FORM FDA 1572:
Copies of Form FDA 1572 with its attachments may be sent by the
Sponsor-Investigator to FDA to satisfy Form FDA 1571, box 12, item 6 b-d. Information can
be supplied in the form of attachments (such as a curriculum vitae) rather than entering
that information directly onto the form, but this should be so noted under the relevant
section numbers.
FDA RECEIPT OF THE IND:
Upon receipt of the IND by FDA, an IND number will be assigned, and the application
will be forwarded to the appropriate reviewing division. The reviewing division will send
a letter to the Sponsor-Investigator providing notification of the IND number assigned,
date of receipt of the original application, address where future submissions to the IND
should be sent, and the name and telephone number of the FDA person to whom questions
about the application should be directed. Studies shall not be initiated until 30 days
after the date of receipt of the IND by FDA unless you receive earlier notification by FDA
that studies may begin.
 Back
to Top 
Back to Drug Info
Date created: December 9, 1998; Updated October 7, 2004 |
|
